Country/Region

MSF International President, Dr. Unni Karunakara, in his keynote speech at the 2012 Universities Allied for Essential Medicines conference:

More >

An open letter to Joe Jiminez and Daniel Vassella, the CEO and President of Novartis, respectively. 

More >

This letter was sent to Heads of State or Governments of Member States of the European Union, to Presidents of European Institutions, and to the offices of the UN High Commissioner for Refugees, the UN High Commissioner for Human Rights, and the International Organisation for Migration.

More >

I am writing on behalf of MSF to express our disappointment that J&J has not yet placed any patent into the Medicines Patent Pool and that it has announced in a recent letter to the Medicines Patent Pool that it is not ready to engage in formal negotiations.

More >

"We seek increased access to affordable lifesaving medicines, vaccines and diagnostic tools in developing countries and to stimulate the development of urgently needed better tools for our field teams and people in countries where MSF works."

More >

An open letter from Sophie Delaunay, Executive Director of MSF-USA, urging the U.S. to stop supplying nutritionally substandard food to malnourished children in developing countries.

More >

Innovation and Access for Neglected Diseases: The Experience of Médecins Sans Frontières

U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing

Oral Statement of
Suerie Moon
Board of Directors
Doctors Without Borders/Médecins Sans Frontières - USA
July 21, 2010, 10am
430 Dirksen Senate Office Building

Thank you, Chairperson Harkin, Ranking Member Enzi, and the Committee.

More >

NY Times Lettter-to-the-Editor on MSF concerns that a provision in proposed U.S. health care legislation will allow pharmaceutical companies to extend monopolies on high-priced, cutting-edge medicines.

More >

MSF testified at a hearing before the US Trade Representative about the effect of US trade and intellectual property pressures on global health policy and efforts to expand access to affordable medicines in developing countries.

More >

Doctors Without Borders is urging law makers to revise a provision in the U.S. health care legislation that would essentially allow pharmaceutical companies to extend their monopolies on a rapidly expanding and high-priced brand of drugs known as biologics. Biologics--medicines derived from living cells--hold great promise for new vaccines and medicines. Unfortunately, the biologics provision in the current legislation will create a massive barrier to developing generic versions of these cutting-edge drugs.

More >

Pages